BUZZ-Aurinia Pharmaceuticals Inc: Positive kidney drug study

Mon Feb 8, 2016 11:42am EST
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

** Canadian drug maker's U.S. listed shares up 22 pct at $2.67; shares rise as much as 51 pct to $3.30 earlier, their biggest percentage gain in more than 2 years

** Says its experimental drug, Voclosporin, reduced excessive protein in urine by 25 pct in patients with lupus nephritis at 8 weeks of treatment

** Condition of excessive protein in urine, or Proteinuria, indicates a significant risk of renal disease

** Voclosporin is being studied as a potential treatment for lupus nephritis, or an inflammation of the kidneys

** Up to Friday's close, stock had fallen 37 pct in the past 12 months